This commentary emphasizes that lifetime management of severe aortic stenosis must adapt to rapidly evolving technologies, suggesting TAVR explantation is becoming a mature, planned strategy rather than a prohibitive rescue operation.
We read with great interest the thoughtful article by Hamana and colleagues regarding lifetime management and reintervention after transcatheter aortic valve replacement (TAVR) (1). Their review appropriately highlights the growing importance of structural valve deterioration as TAVR expands into younger and lower-risk populations and provides an excellent overview of the pathological mechanisms underlying bioprosthetic valve failure. We agree that reintervention is no longer an exceptional event but an anticipated component of caring for patients with severe aortic stenosis. We would, however
No takes yet. Share an insight, caveat, or question.
Hon et al. (2026) conducted a letter in Severe aortic stenosis. TAVR-first strategy followed by planned TAVR explantation vs. SAVR-first strategy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: